Figure 6.
BTKi therapy and CTLA-4 blockade by ipilimumab enhance the cytotoxic effector function of autologous and allogeneic T cells in response to CD19/CD3 bsAb. (A) CLL PBMCS from BTKi-naïve (BN, n = 6) patients were cultured with CD19/CD3 bsAb with or without the addition of ipilimumab (50 μg/mL). Depicted is the specific killing of CLL cells after 3 days of culture. (B) Purified CLL cells obtained from the same CLL patients before starting therapy (baseline) and after at least 6 months on BTKi therapy (BTKi) (n = 6), were incubated with or without ipilimumab for 24 hours before coculture with CD19/CD3 bsAb and healthy donor allogeneic T cells, at a 1:10 E:T ratio. Depicted is the specific killing of CLL cells after 3 days of culture. Results are reported as median and IQR. Statistical significance by Wilcoxon matched-pair signed-rank test. *P < .05.

BTKi therapy and CTLA-4 blockade by ipilimumab enhance the cytotoxic effector function of autologous and allogeneic T cells in response to CD19/CD3 bsAb. (A) CLL PBMCS from BTKi-naïve (BN, n = 6) patients were cultured with CD19/CD3 bsAb with or without the addition of ipilimumab (50 μg/mL). Depicted is the specific killing of CLL cells after 3 days of culture. (B) Purified CLL cells obtained from the same CLL patients before starting therapy (baseline) and after at least 6 months on BTKi therapy (BTKi) (n = 6), were incubated with or without ipilimumab for 24 hours before coculture with CD19/CD3 bsAb and healthy donor allogeneic T cells, at a 1:10 E:T ratio. Depicted is the specific killing of CLL cells after 3 days of culture. Results are reported as median and IQR. Statistical significance by Wilcoxon matched-pair signed-rank test. *P < .05.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal